222 related articles for article (PubMed ID: 28619709)
1. Loss of
Zhu YX; Shi CX; Bruins LA; Jedlowski P; Wang X; Kortüm KM; Luo M; Ahmann JM; Braggio E; Stewart AK
Cancer Res; 2017 Aug; 77(16):4317-4327. PubMed ID: 28619709
[No Abstract] [Full Text] [Related]
2. The non-canonical poly(A) polymerase FAM46C acts as an onco-suppressor in multiple myeloma.
Mroczek S; Chlebowska J; Kuliński TM; Gewartowska O; Gruchota J; Cysewski D; Liudkovska V; Borsuk E; Nowis D; Dziembowski A
Nat Commun; 2017 Sep; 8(1):619. PubMed ID: 28931820
[TBL] [Abstract][Full Text] [Related]
3. Biallelic loss of FAM46C triggers tumor growth with concomitant activation of Akt signaling in multiple myeloma cells.
Kanasugi J; Hanamura I; Ota A; Karnan S; Lam VQ; Mizuno S; Wahiduzzaman M; Rahman ML; Hyodo T; Konishi H; Tsuzuki S; Hosokawa Y; Takami A
Cancer Sci; 2020 May; 111(5):1663-1675. PubMed ID: 32176823
[TBL] [Abstract][Full Text] [Related]
4. FAM46C controls antibody production by the polyadenylation of immunoglobulin mRNAs and inhibits cell migration in multiple myeloma.
Herrero AB; Quwaider D; Corchete LA; Mateos MV; García-Sanz R; Gutiérrez NC
J Cell Mol Med; 2020 Apr; 24(7):4171-4182. PubMed ID: 32141701
[TBL] [Abstract][Full Text] [Related]
5. FAM46C and FNDC3A Are Multiple Myeloma Tumor Suppressors That Act in Concert to Impair Clearing of Protein Aggregates and Autophagy.
Manfrini N; Mancino M; Miluzio A; Oliveto S; Balestra M; Calamita P; Alfieri R; Rossi RL; Sassoè-Pognetto M; Salio C; Cuomo A; Bonaldi T; Manfredi M; Marengo E; Ranzato E; Martinotti S; Cittaro D; Tonon G; Biffo S
Cancer Res; 2020 Nov; 80(21):4693-4706. PubMed ID: 32963011
[TBL] [Abstract][Full Text] [Related]
6. The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in
Díaz T; Rodríguez V; Lozano E; Mena MP; Calderón M; Rosiñol L; Martínez A; Tovar N; Pérez-Galán P; Bladé J; Roué G; de Larrea CF
Haematologica; 2017 Oct; 102(10):1776-1784. PubMed ID: 28751557
[TBL] [Abstract][Full Text] [Related]
7. The Interaction of the Tumor Suppressor FAM46C with p62 and FNDC3 Proteins Integrates Protein and Secretory Homeostasis.
Fucci C; Resnati M; Riva E; Perini T; Ruggieri E; Orfanelli U; Paradiso F; Cremasco F; Raimondi A; Pasqualetto E; Nuvolone M; Rampoldi L; Cenci S; Milan E
Cell Rep; 2020 Sep; 32(12):108162. PubMed ID: 32966780
[TBL] [Abstract][Full Text] [Related]
8. The Immunity-malignancy equilibrium in multiple myeloma: lessons from oncogenic events in plasma cells.
Perini T; Materozzi M; Milan E
FEBS J; 2022 Aug; 289(15):4383-4397. PubMed ID: 34117720
[TBL] [Abstract][Full Text] [Related]
9. Structural and functional characterization of multiple myeloma associated cytoplasmic poly(A) polymerase FAM46C.
Zhang H; Zhang SH; Hu JL; Wu YT; Ma XY; Chen Y; Yu B; Liao S; Huang H; Gao S
Cancer Commun (Lond); 2021 Jul; 41(7):615-630. PubMed ID: 34048638
[TBL] [Abstract][Full Text] [Related]
10. FAM46C-mediated tumor heterogeneity predicts extramedullary metastasis and poorer survival in multiple myeloma.
Zhang W; Wu C; Geng S; Wang J; Yan C; Zhang X; Zhang JJ; Wu F; Pang Y; Zhong Y; Wang J; Fu W; Huang X; Wang W; Lyu X; Huang Y; Jing H
Aging (Albany NY); 2023 May; 15(9):3644-3677. PubMed ID: 37155154
[TBL] [Abstract][Full Text] [Related]
11. FAM46C inhibits lipopolysaccharides-induced myocardial dysfunction via downregulating cellular adhesion molecules and inhibiting apoptosis.
Tan J; Sun T; Shen J; Zhu H; Gong Y; Zhu H; Wu G
Life Sci; 2019 Jul; 229():1-12. PubMed ID: 30910647
[TBL] [Abstract][Full Text] [Related]
12. Serum/glucocorticoid-regulated kinase 1 (SGK1) is a prominent target gene of the transcriptional response to cytokines in multiple myeloma and supports the growth of myeloma cells.
Fagerli UM; Ullrich K; Stühmer T; Holien T; Köchert K; Holt RU; Bruland O; Chatterjee M; Nogai H; Lenz G; Shaughnessy JD; Mathas S; Sundan A; Bargou RC; Dörken B; Børset M; Janz M
Oncogene; 2011 Jul; 30(28):3198-206. PubMed ID: 21478911
[TBL] [Abstract][Full Text] [Related]
13. Cyclin D1 sensitizes myeloma cells to endoplasmic reticulum stress-mediated apoptosis by activating the unfolded protein response pathway.
Bustany S; Cahu J; Guardiola P; Sola B
BMC Cancer; 2015 Apr; 15():262. PubMed ID: 25881299
[TBL] [Abstract][Full Text] [Related]
14. Amiloride, An Old Diuretic Drug, Is a Potential Therapeutic Agent for Multiple Myeloma.
Rojas EA; Corchete LA; San-Segundo L; Martínez-Blanch JF; Codoñer FM; Paíno T; Puig N; García-Sanz R; Mateos MV; Ocio EM; Misiewicz-Krzeminska I; Gutiérrez NC
Clin Cancer Res; 2017 Nov; 23(21):6602-6615. PubMed ID: 28790111
[No Abstract] [Full Text] [Related]
15. Comprehensive characterization of the mutational landscape in multiple myeloma cell lines reveals potential drivers and pathways associated with tumor progression and drug resistance.
Vikova V; Jourdan M; Robert N; Requirand G; Boireau S; Bruyer A; Vincent L; Cartron G; Klein B; Elemento O; Kassambara A; Moreaux J
Theranostics; 2019; 9(2):540-553. PubMed ID: 30809292
[TBL] [Abstract][Full Text] [Related]
16. FAM46C is critical for the anti-proliferation and pro-apoptotic effects of norcantharidin in hepatocellular carcinoma cells.
Zhang QY; Yue XQ; Jiang YP; Han T; Xin HL
Sci Rep; 2017 Mar; 7(1):396. PubMed ID: 28341836
[TBL] [Abstract][Full Text] [Related]
17. Differential Expression of MicroRNA-19b Promotes Proliferation of Cancer Stem Cells by Regulating the TSC1/mTOR Signaling Pathway in Multiple Myeloma.
Wang N; Liang X; Yu W; Zhou S; Fang M
Cell Physiol Biochem; 2018; 50(5):1804-1814. PubMed ID: 30396185
[TBL] [Abstract][Full Text] [Related]
18. Protein kinase CK2 protects multiple myeloma cells from ER stress-induced apoptosis and from the cytotoxic effect of HSP90 inhibition through regulation of the unfolded protein response.
Manni S; Brancalion A; Tubi LQ; Colpo A; Pavan L; Cabrelle A; Ave E; Zaffino F; Di Maira G; Ruzzene M; Adami F; Zambello R; Pitari MR; Tassone P; Pinna LA; Gurrieri C; Semenzato G; Piazza F
Clin Cancer Res; 2012 Apr; 18(7):1888-900. PubMed ID: 22351691
[TBL] [Abstract][Full Text] [Related]
19. KDM6B modulates MAPK pathway mediating multiple myeloma cell growth and survival.
Ohguchi H; Harada T; Sagawa M; Kikuchi S; Tai YT; Richardson PG; Hideshima T; Anderson KC
Leukemia; 2017 Dec; 31(12):2661-2669. PubMed ID: 28487543
[TBL] [Abstract][Full Text] [Related]
20. Non-canonical NFκB mutations reinforce pro-survival TNF response in multiple myeloma through an autoregulatory RelB:p50 NFκB pathway.
Roy P; Mukherjee T; Chatterjee B; Vijayaragavan B; Banoth B; Basak S
Oncogene; 2017 Mar; 36(10):1417-1429. PubMed ID: 27641334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
